Welcome to our dedicated page for Pasithea Therapeutics Warrants news (Ticker: KTTAW), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics Warrants stock.
Pasithea Therapeutics Corp is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. Leveraging expertise in neuroscience, translational medicine, and drug development, the company's pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announces the invention of a crystalline form of PAS-004, extending patent protection to at least 2045. The company is focused on developing innovative treatments for CNS disorders, with a strong emphasis on expanding its patent portfolio and increasing the value of PAS-004 through additional CMC development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.03%
Tags
-
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the FDA clearance to evaluate PAS-004, a macrocyclic MEK inhibitor, in patients with MAPK pathway driven advanced solid tumors. The phase 1 dose escalation study is expected to begin in Q1 2024, with an initial readout anticipated as early as Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.78%
Tags
-
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) adjourns stockholder meeting to provide additional time for voting on charter amendment proposals. The reconvened meeting will take place on December 29, 2023, with the original record date remaining the same. Stockholders are encouraged to vote promptly, and proxies previously submitted will be voted at the adjourned meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.13%
Tags
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) Holds Annual Meeting and Receives Overwhelming Support for Approved Proposals
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.58%
Tags
-
Rhea-AI Summary
Pasithea Therapeutics Corp. (KTTA) announced positive preclinical results for PAS-004, a potential treatment for Central Nervous System disorders. PAS-004 demonstrated superior anti-tumor efficacy in lung and liver cancer models compared to FDA-approved MEK inhibitors. The company plans to start a Phase 1 trial in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
47.33%
Tags
-
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) adjourns its annual meeting of stockholders to December 19, 2023, to allow additional time for stockholders to vote on proposals outlined in the Proxy Statement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.91%
Tags
News
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) plans to submit PAS-004 IND application in the current quarter and begin a Phase 1 dose escalation trial in advanced solid tumor patients harboring RAS, RAF, and NF1 mutations. The FDA's positive feedback and guidance include a recommendation to begin dosing in patients who will benefit from treatment rather than in healthy volunteers. PAS-004 was granted orphan drug designation for the treatment of NF1 in November 2020. Dr. Tiago Reis Marques, CEO of Pasithea, expressed excitement to begin testing PAS-004 in a first-in-human Phase 1 dose escalation trial in early 2024 following acceptance of the IND by the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.63%
Tags
-
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the selection of a lead therapeutic candidate for its PAS-003 program, a humanized monoclonal antibody targeting α5β1 integrin, showing promise for the treatment of ALS. The antibody has been optimized for high affinity and specificity, ready for manufacturing and IND-enabling studies. Extensive preclinical studies have validated the candidate's efficacy in both sporadic and familial ALS mouse models, with potential implications for human patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Pasithea Therapeutics Corp. completes tender offer, purchasing all 5,323,451 shares at $0.70 per share
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
News
Rhea-AI Summary
Pasithea Therapeutics Corp. to participate in H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.2%
Tags
FAQ
What is the current stock price of Pasithea Therapeutics Warrants (KTTAW)?
The current stock price of Pasithea Therapeutics Warrants (KTTAW) is $0.0252 as of November 1, 2024.
What is Pasithea Therapeutics Corp focused on?
Pasithea Therapeutics Corp is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies.
What is included in Pasithea Therapeutics Corp's pipeline?
The company's pipeline includes treatments for Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.
What areas of expertise does Pasithea Therapeutics Corp leverage?
Pasithea Therapeutics Corp leverages expertise in neuroscience, translational medicine, and drug development.
Who can be contacted for corporate communications at Pasithea Therapeutics Corp?
For corporate communications, you can reach out to Patrick Gaynes at pgaynes@pasithea.com.
When is the initial safety, tolerability, and biomarker data expected to be reported?
The initial safety, tolerability, and biomarker data are expected to be reported in the second half of 2024.
When is the initial interim safety and PK data release on track for?
The initial interim safety and PK data release is on track for the third quarter of 2024.
What diseases does Pasithea Therapeutics Corp focus on?
Pasithea Therapeutics Corp focuses on treating central nervous system (CNS) disorders, RASopathies, and other diseases.
What is Pasithea Therapeutics Corp's primary area of research?
The company's primary area of research is in developing treatments for central nervous system (CNS) disorders.
What is the core mission of Pasithea Therapeutics Corp?
The core mission of Pasithea Therapeutics Corp is to advance the treatment options for patients with CNS disorders and other related conditions.
How does Pasithea Therapeutics Corp contribute to the field of medicine?
Pasithea Therapeutics Corp contributes by developing innovative therapies for challenging conditions like Neurofibromatosis Type 1, ALS, MS, and Schizophrenia.
Pasithea Therapeutics Corp. Warrants